Latest News

Experimental Alzheimer’s drug boosts SirT1 levels and improves memory in mice.

Researchers at the Drug Discovery Lab (DDL) at the Mary S. Easton Center for Alzheimer's Disease Research at UCLA have recently reported that an experimental drug known as A03, previously developed to treat depression, was found to increase brain levels of an enzyme Sirtuin1, or SirT1, and improve memory after oral treatment in mice genetically modified to have a protein called ApoE4, the most common genetic risk factor for AD. Increasing the levels of SirT1 may delay the buildup of the toxic tau pathology and improve cognition in Alzheimer's. The  DDL is conducting additional research on A03 to evaluate its potential for clinical testing in Alzheimer's disease. The lab is also developing similar compounds that might be more effective in increasing SirT1 levels.  The study was funded by the National Institute of Health.

UCLA Newsroom Research Alert - December 20, 2018:
"Experimental Alzheimer’s drug boosts SirT1 levels and improves memory in mice."

Researchers discover drug that could combat brain cell death in those with Alzheimer’s disease.

Dr. Lin Jiang, Assistant Professor of Neurology at David Geffen School of Medicine at UCLA, was featured in an October 22 UCLA Newsroom article about him and his team members identified the plaque binding site of b-amyloid to its receptor by determining the three-dimensional structure. Knowledge of this interaction is a critical first step toward finding a drug to prevent the interaction between the toxic proteins and brain cells. Dr. Jiang and his team are using computer software to assist them in the drug selection process.

Alzheimer's Association® - AAIC 2018 News Highlights

The Alzheimer’s Association® - is committed to advocating awareness of latest Alzheimer’s research and resources. Each year, the organization brings together the world’s renowned basic science and clinical researchers, early career investigators, clinicians and the care research community to share advancements in dementia science and explore the latest information on products and services. Please visit the Alzheimer’s Association® website for the Alzheimer’s Association International Conference (AAIC) 2018 news highlights.

Molecule halts spread of toxic protein associated with Alzheimer’s.

UCLA Newsroom, EurekAlert, Science Magazine, Science Daily, Drug Discovery and Development, Health Canal, Medical Express, Scicasts and Medicine News Line reported on research showing a promising new drug strategy to halt tau transmission to treat Alzheimer’s. Varghese John, an Associate Professor of Neurology at the David Geffen School of Medicine at UCLA, and Karen Gylys, a Professor at the School of Nursing, were quoted.

Disrupted sleep-wake cycle might be a measure for preclinical Alzheimer’s.

National Institute of Health – National Institute on Aging - Report - Disrupted sleep-wake cycle might be a measure for preclinical Alzheimer's - People with dementia due to Alzheimer’s disease are known to have disrupted sleep. New NIH-funded research, published online Jan. 29, 2018, in JAMA Neurology, links a disrupted sleep-wake cycle to an earlier, preclinical disease phase, in which people have evidence of the disease but no symptoms. The study, by researchers at the Knight Alzheimer's Disease Research Center at Washington University in St. Louis, Missouri, suggests that a fragmented sleep-wake cycle might be explored as a biomarker for preclinical Alzheimer's.